Bansal Nidhi
Nidhi Bansal, Department of Pediatrics, Section of Pediatric Diabetes and Endocrinology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX 77030, United States.
World J Diabetes. 2015 Mar 15;6(2):296-303. doi: 10.4239/wjd.v6.i2.296.
Prediabetes is an intermediate state of hyperglycemia with glycemic parameters above normal but below the diabetes threshold. While, the diagnostic criteria of prediabetes are not uniform across various international professional organizations, it remains a state of high risk for developing diabetes with yearly conversion rate of 5%-10%. Observational evidence suggests as association between prediabetes and complications of diabetes such early nephropathy, small fiber neuropathy, early retinopathy and risk of macrovascular disease. Several studies have shown efficacy of lifestyle interventions with regards to diabetes prevention with a relative risk reduction of 40%-70% in adults with prediabetes. While there is increasing evidence to prove the efficacy of pharmacotherapy in prevention of diabetes in adults with prediabetes, pharmaceutical treatment options other than metformin are associated with adverse effects that limit their use for prediabetes. There are no reports of systematic evaluation of health outcomes related to prediabetes in children. The effects of pharmacotherapy of prediabetes on growth and pubertal development in children remains unknown. Secondary intervention with pharmacotherapy with metformin is advocated for high-risk individuals but criteria for such consideration benefit of early intervention, long term cost effectiveness of such interventions and the end point of therapy remain unclear. Pharmacotherapy must be used with caution in children with prediabetes. Prediabetes is a condition defined as having blood glucose levels above normal but below the defined threshold of diabetes. It is considered to be an at risk state, with high chances of developing diabetes. While, prediabetes is commonly an asymptomatic condition, there is always presence of prediabetes before the onset of diabetes. The elevation of blood sugar is a continuum and hence prediabetes can not be considered an entirely benign condition. This aim of this review is to describe the challenges associated with diagnosis of prediabetes, the possible adverse medical outcomes associated with prediabetes and the treatment options and rationale for their use in context of prediabetes.
糖尿病前期是一种血糖水平高于正常但低于糖尿病阈值的高血糖中间状态。尽管不同国际专业组织对糖尿病前期的诊断标准并不统一,但它仍是发生糖尿病的高危状态,年转化率为5%-10%。观察性证据表明,糖尿病前期与糖尿病并发症如早期肾病、小纤维神经病变、早期视网膜病变以及大血管疾病风险之间存在关联。多项研究表明,生活方式干预对预防糖尿病有效,糖尿病前期成年人的相对风险降低40%-70%。虽然越来越多的证据证明药物治疗对预防糖尿病前期成年人患糖尿病有效,但除二甲双胍外的药物治疗选择都伴有不良反应,限制了它们在糖尿病前期的应用。目前尚无关于儿童糖尿病前期相关健康结局的系统评估报告。糖尿病前期药物治疗对儿童生长和青春期发育的影响仍不清楚。对于高危个体,主张使用二甲双胍进行二级药物干预,但这种早期干预的获益标准、此类干预的长期成本效益以及治疗终点仍不明确。糖尿病前期儿童使用药物治疗必须谨慎。糖尿病前期是指血糖水平高于正常但低于糖尿病定义阈值的一种状态。它被认为是一种高危状态,发展为糖尿病的可能性很大。虽然糖尿病前期通常无症状,但在糖尿病发病之前总是存在糖尿病前期状态。血糖升高是一个连续过程,因此不能认为糖尿病前期是一种完全良性的状态。本综述的目的是描述糖尿病前期诊断相关的挑战、与糖尿病前期相关的可能不良医学结局以及在糖尿病前期背景下的治疗选择及其使用原理。